Shareholders Have Until 30th June 2026
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has announced an extension for the deadline regarding payment instructions for its special cash dividend. Shareholders and brokers now have until 30th June 2026 to submit their instructions. This decision offers additional time for those yet to complete the required documentation.
This special cash dividend amounts to USD 55.00 per common share. It is available to shareholders holding shares as of 23rd May 2025. Originally, the deadline for submitting payment instructions was set for 31st December 2025, but it has been pushed back to accommodate all stakeholders.
People who have not submitted their instruction materials are urged to do so before the new deadline to ensure they receive the dividend. D.F. King & Co., Inc., located at 28 Liberty Street, 53rd Floor, New York, NY 10005, serves as the Information Agent and can be contacted for any submission process questions.
Shareholders can reach D.F. King & Co., Inc. via email with the subject line ‘Sinovac Biotech Ltd, Special Dividend’ for assistance.
About Sinovac
Sinovac Biotech Ltd. stands as a prominent global biopharmaceutical company based in China. The company focuses on research, development, manufacturing, and commercialization of vaccines against infectious diseases.
Sinovac’s vaccine portfolio includes products for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease, and polio. Three of their vaccines, including Healive®, an inactivated hepatitis A vaccine, have received prequalification from the World Health Organisation.
With a strong emphasis on combating infectious disease outbreaks, Sinovac was among the first to develop vaccines during major public health emergencies. The company created the world’s first inactivated SARS vaccine, China’s first H5N1 influenza vaccine, and the globally used CoronaVac, an inactivated COVID-19 vaccine.
Continuing innovation, Sinovac is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines, and next-generation platforms such as mRNA technologies. The company is expanding its global presence by partnering with research institutions and international organisations.
For further information, shareholders can visit the company’s official website or contact Helen Yang at Sinovac Biotech for assistance.
